Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01841333 · ClinicalTrials.gov registry record · Phase 2
PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant
A Phase 2 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT01841333 is a Phase 2 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 31 participants.
The verdict
NCT01841333, a Phase 2 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This phase II trial will test whether the Hedgehog signaling pathway inhibitor PF-04449913 can decrease disease relapse in high-risk patients with acute myeloid leukemia after donor stem cell transplant.
Interventions
- DRUG PF-04449913
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2013-04-29 |
| Est. Completion | 2020-02-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01841333
The ClinicalTrials.gov registry entry for NCT01841333 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-04449913 is the first listed.
NCT01841333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01841333 about?
NCT01841333 is a clinical study titled "PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant". This phase II trial will test whether the Hedgehog signaling pathway inhibitor PF-04449913 can decrease disease relapse in high-risk patients with acute myeloid leukemia after donor stem cell transplant.
What is the current status of trial NCT01841333?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2013-04-29. Estimated completion is 2020-02-04.
What interventions are being tested in trial NCT01841333?
The interventions under investigation include: PF-04449913 (DRUG).
Who is sponsoring clinical trial NCT01841333?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.